In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
Open Access
- 6 May 2020
- journal article
- research article
- Published by Springer Nature in Drugs in R&D
- Vol. 20 (3) , 209-216
Abstract
Background Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease. Objective This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms. Methods The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin. Results Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50–70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin. Conclusions Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection.Keywords
Funding Information
- National Health and Medical Research Council (GNT9000198)
This publication has 16 references indexed in Scilit:
- Insights into drug resistance mechanisms in Clostridium difficileEssays in Biochemistry, 2017
- Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New ZealandInternal Medicine Journal, 2016
- Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failureJournal of Antimicrobial Chemotherapy, 2013
- A New Strategy for the Prevention of Clostridium difficile InfectionThe Journal of Infectious Diseases, 2013
- The Clostridium difficile spo0A Gene Is a Persistence and Transmission FactorInfection and Immunity, 2012
- Shifting the balance: antibiotic effects on host–microbiota mutualismNature Reviews Microbiology, 2011
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adductJBIC Journal of Biological Inorganic Chemistry, 2009
- Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanideJournal of Antimicrobial Chemotherapy, 2007
- Regulated transcription of Clostridium difficile toxin genesMolecular Microbiology, 1998